Telix Doses First Patient in Phase 3 Glioblastoma Trial
Melbourne, Australia & Indianapolis, Indiana, U.S. | April 15, 2026 Telix Pharmaceuticals has announced a major clinical milestone with...
cancer therapy
Advertisement
Telix and Regeneron Partner to Advance Radiopharma Therapies
Melbourne, Australia & Tarrytown, New York | April 13, 2026 Telix Pharmaceuticals and Regeneron Pharmaceuticals have announced a strategic...
Replimune RP1 Melanoma Drug Faces FDA Rejection
Woburn, Massachusetts | April 10, 2026 Replimune Group Inc. has announced that the U.S. Food and Drug Administration (FDA)...
IDEAYA to Reveal Phase 3 Melanoma Trial Results Soon
South San Francisco, California | April 10, 2026 IDEAYA Biosciences has announced that it will disclose topline results from...
Oxford BioTherapeutics, Bristol Myers Squibb Advance T-Cell Therapies
Oxford, United Kingdom & San Jose, California | April 9, 2026 Oxford BioTherapeutics (OBT) has announced a strategic collaboration...
Advertisements
Kymera-Gilead Deal Advances CDK2 Cancer Therapy
WATERTOWN, Massachusetts, April 9, 2026 Kymera Therapeutics has announced that Gilead Sciences has exercised its option to exclusively license...
DualityBio Advances HER2 ADC Toward China Approval
SHANGHAI, China, April 9, 2026 DualityBio has announced that the China National Medical Products Administration (NMPA) has accepted the...
C4 and Roche Expand DAC Cancer Drug Collaboration
WATERTOWN, Mass., April 09, 2026 C4 Therapeutics, Inc. has announced a major expansion of its long-term collaboration with Roche,...
Gilead Acquires Tubulis to Boost Oncology Pipeline
FOSTER CITY, California, United States & MUNICH, Germany, April 7, 2026 Gilead Sciences, Inc. announced a definitive agreement to...
Cogent Biosciences Files NDA for Bezuclastinib in GIST
WALTHAM, Mass. and BOULDER, Colo., April 1, 2026 Cogent Biosciences, Inc. has announced the successful submission of a New...
Advertisement
